Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 13/20 | 0.44 |
| ▸ | MTTP | P55157 | 2/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20924668 | 0.84 | KDM1A (0.56) | KDM1A | |
| SCHEMBL16455170 | 0.82 | EPHX2 (0.45) | KDM1AMTTPCD274EPHX2 | |
| SCHEMBL19466085 | 0.81 | CD274 (0.43) | KDM1AMTTPCD274EPHX2 | |
| SCHEMBL18848759 | 0.81 | F2 (0.49) | KDM1AMTTPCD274EPHX2 | |
| SCHEMBL19466069 | 0.80 | KDM1A (0.59) | KDM1A | |
| SCHEMBL18059527 | 0.80 | KDM1A (0.59) | KDM1A | |
| SCHEMBL20924673 | 0.80 | KDM1A (0.51) | KDM1A | |
| SCHEMBL16447253 | 0.79 | KDM1A (0.53) | KDM1A | |
| SCHEMBL16447254 | 0.79 | KDM1A (0.53) | KDM1A | |
| SCHEMBL16455163 | 0.79 | KDM1A (0.53) | KDM1ACD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655226-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-20210147373-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2021-05-20 | — | — | US | disclosed |
| US-10370346-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20170334873-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334873-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | KDM1A 2/4885MTTP 2656/4885CD274 2618/4885 |
| US-10370346-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | KDM1A 2/4885MTTP 2656/4885CD274 2618/4885 |
| US-20210147373-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | KDM1A 2/4885MTTP 2656/4885CD274 2618/4885 |
| US-11655226-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | KDM1A 2/4885MTTP 2656/4885CD274 2618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.